| Literature DB >> 7488407 |
P A Ellis1, A Norman, A Hill, M E O'Brien, M Nicolson, T Hickish, D Cunningham.
Abstract
Hepatobiliary tumours are rare, often present late and have a poor prognosis, with no current effective systemic therapy available. This study aimed to evaluate the activity and toxicity of epirubicin, cisplatin and continuous infusional 5-fluorouracil (5-FU) (ECF) in patients with these tumours. From March 1991 to November 1993, 25 patients with advanced biliary tumours and 7 with hepatoma were treated with epirubicin 50 mg/m2 and cisplatin 60 mg/m2 intravenously (i.v.) day 1, each given every 21 days and 5-FU 200 mg/m2/day given as a continuous 24 h i.v. infusion throughout the treatment course. 8 of the 20 (40%) evaluable patients with biliary tumours responded. Median duration of response was 10 months. 2 of the 7 (29%) patients with hepatoma responded. The regimen was well tolerated with minimal haematological and non-haematological toxicity. This novel regimen is active in advanced hepatobiliary tumours.Entities:
Mesh：
Substances：
Year: 1995 PMID： 7488407 DOI： 10.1016/0959-8049(95)00323-b
Source DB: PubMed Journal: Eur J Cancer ISSN： 0959-8049 Impact factor: 9.162